Accelerated Approval: Complete FDA Pathway Guide for Drug Sponsors
Accelerated approval is an FDA pathway enabling drug approval based on surrogate endpoints that predict clinical benefit, bypassing the need for clinical outcome data. This expedited route is designed for serious conditions with unmet medical needs, but requires sponsors to complete postmarketing confirmatory trials to verify actual patient benefit-and carries the risk of withdrawal if those trials fail.
Accelerated approval is an FDA expedited program that allows drugs to be approved based on a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit, rather than waiting for definitive evidence of how the drug affects disease outcomes. This pathway is specifically designed for serious conditions with unmet medical needs where earlier access to promising therapies can provide meaningful patient benefits.
For drug sponsors developing therapies for cancer, rare diseases, or other serious conditions, understanding the accelerated approval pathway can mean the difference between years of additional trials and getting a life-saving treatment to patients who desperately need it. However, this pathway comes with significant postmarketing obligations - and recent FDA reforms have added new accountability measures that every sponsor must understand.
In this guide, you'll learn:
- How the FDA accelerated approval pathway works and who qualifies
- The role of surrogate endpoints in accelerated approval drugs
- Confirmatory trial requirements and the consequences of failure
- How FDORA reforms changed the accelerated approval landscape
- Comparison of accelerated approval with other FDA expedited programs
What Is Accelerated Approval? Understanding FDA's Expedited Pathway
Accelerated approval - A regulatory pathway established by FDA (21 CFR Part 314 Subpart H for drugs; 21 CFR Part 601 Subpart E for biologics) that permits marketing approval based on evidence of drug efficacy on a surrogate endpoint reasonably likely to predict clinical benefit, rather than requiring definitive evidence of direct clinical outcomes. Limited to serious or life-threatening conditions with unmet medical needs, and conditioned on postmarketing confirmatory trials.
Accelerated approval is a regulatory pathway established by FDA under 21 CFR Part 314 Subpart H (for drugs) and 21 CFR Part 601 Subpart E (for biologics) that allows marketing approval based on evidence that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. This pathway was created to address the urgent need for earlier patient access to promising therapies for serious conditions.
Key characteristics of accelerated approval:
- Requires a surrogate endpoint or intermediate clinical endpoint reasonably likely to predict clinical benefit
- Limited to drugs treating serious or life-threatening conditions
- Must address an unmet medical need - provide benefit over available therapy
- Requires postmarketing confirmatory trials to verify clinical benefit
- Subject to expedited withdrawal procedures if confirmatory trials fail
Since the accelerated approval program began in 1992, FDA has granted more than 300 accelerated approvals, with approximately 60% of these being for oncology indications (FDA, 2024).
The accelerated approval pathway fundamentally changes the traditional drug approval paradigm. Instead of requiring sponsors to demonstrate that a drug directly improves survival or reduces disease symptoms - which can take years to observe - FDA allows approval based on biomarkers or intermediate endpoints that predict those benefits. This approach can reduce approval timelines by several years for critical therapies.
How FDA Accelerated Approval Works: The Complete Process
The FDA accelerated approval process involves multiple stages, from initial designation through postmarketing surveillance. Understanding each phase helps sponsors plan their development programs effectively.
Step 1: Determining Accelerated Approval Eligibility
Before pursuing accelerated approval, sponsors must assess whether their drug candidate meets the fundamental criteria. The FDA accelerated approval pathway has three core requirements that must all be satisfied:
| Requirement | Definition | Examples |
|---|---|---|
| Serious Condition | Disease with substantial impact on day-to-day functioning or is life-threatening | Cancer, HIV/AIDS, Alzheimer's disease, heart failure |
| Unmet Medical Need | Meaningful advantage over existing treatments | First treatment for a condition, improved efficacy, better safety profile |
| Surrogate Endpoint | Reasonably likely to predict clinical benefit | Tumor response rate, CD4 cell count, viral load reduction |
Step 2: Early FDA Engagement
Sponsors should engage FDA early to discuss the appropriateness of the accelerated approval pathway. Critical meetings include:
Pre-IND Meeting: Discuss whether the condition qualifies as serious and whether proposed surrogate endpoints have regulatory precedent.
End-of-Phase 2 Meeting: Present surrogate endpoint strategy and confirmatory trial design. This is the critical meeting for accelerated approval pathway alignment.
Pre-NDA/BLA Meeting: Finalize submission strategy and postmarketing commitment details.
“Regulatory Insight: FDA recommends sponsors request accelerated approval pathway discussions as early as possible. The agency's guidance specifically notes that "sponsors should consider requesting a meeting to discuss their development plans, including the appropriateness of pursuing accelerated approval" (FDA Guidance for Industry, 2014).
Document every FDA recommendation regarding surrogate endpoints in writing. Before the IND application, send a post-meeting summary letter to FDA confirming your mutual understanding of the accelerated approval pathway. This creates a shared commitment and reduces the risk of FDA requesting different data later in development.
Step 3: Surrogate Endpoint Selection and Validation
Selecting the right surrogate endpoint is critical for FDA accelerated approval success. FDA categorizes surrogate endpoints into three tiers:
| Surrogate Type | Definition | Regulatory Status | Example |
|---|---|---|---|
| Validated Surrogate | Established scientific evidence linking surrogate to clinical outcome | Accepted for traditional approval | LDL cholesterol for cardiovascular events |
| Reasonably Likely Surrogate | Scientific evidence suggests link but not fully established | Accepted for accelerated approval | Overall response rate in oncology |
| Candidate Surrogate | Preliminary evidence only | Further study required | Novel biomarkers under investigation |
For accelerated approval, FDA requires surrogate endpoints in the "reasonably likely" category. These endpoints must have biological plausibility, epidemiological evidence, and ideally some clinical trial evidence supporting their predictive value.
Step 4: NDA or BLA Submission
The accelerated approval application follows the standard NDA (New Drug Application) or BLA (Biologics License Application) format but includes specific elements:
- Detailed justification for surrogate endpoint selection
- Description of planned confirmatory trials
- Proposed timeline for confirmatory trial completion
- Draft labeling noting the accelerated approval status
Step 5: Postmarketing Commitments
Upon accelerated approval, sponsors must fulfill postmarketing requirements (PMRs) to verify clinical benefit. These commitments are legally binding and subject to enforcement.
Surrogate Endpoints FDA Requirements: The Foundation of Accelerated Approval
Surrogate endpoints are the cornerstone of the accelerated approval pathway. Understanding what FDA requires for surrogate endpoint acceptance is essential for successful submissions.
What Are Surrogate Endpoints?
A surrogate endpoint is a biomarker intended to substitute for a clinical endpoint. A clinical endpoint directly measures how a patient feels, functions, or survives. A surrogate endpoint indirectly measures these outcomes through a biological marker.
| Endpoint Type | Definition | Examples | Use in Approval |
|---|---|---|---|
| Clinical Endpoint | Direct measure of patient benefit | Overall survival, symptom improvement | Traditional approval |
| Surrogate Endpoint | Indirect measure reasonably likely to predict clinical benefit | Tumor shrinkage, viral load | Accelerated approval |
| Intermediate Clinical Endpoint | Measure of therapeutic effect that may predict clinical benefit | Progression-free survival | Accelerated approval |
FDA-Accepted Surrogate Endpoints for Accelerated Approval
FDA maintains a list of surrogate endpoints that have been used for accelerated approval. Understanding these precedents helps sponsors select appropriate endpoints:
Oncology Surrogate Endpoints:
- Overall response rate (ORR)
- Complete response rate
- Duration of response
- Pathological complete response (pCR) in neoadjuvant settings
- Minimal residual disease (MRD) negativity
HIV/AIDS Surrogate Endpoints:
- CD4 cell count
- HIV viral load (RNA copies/mL)
- Virologic response
Cardiovascular Surrogate Endpoints:
- LDL cholesterol reduction
- Blood pressure reduction
Rare Disease Surrogate Endpoints:
- Enzyme activity levels (lysosomal storage disorders)
- Biomarker normalization
- Imaging endpoints
“Critical Note: Even when using established surrogate endpoints, sponsors must demonstrate their relevance to the specific patient population and disease context. A surrogate endpoint accepted for one indication may not be appropriate for another.
Surrogate Endpoint Validation Requirements
FDA evaluates surrogate endpoints based on several factors:
- Biological Plausibility: Is there a scientific rationale linking the surrogate to clinical benefit?
- Epidemiological Evidence: Do observational studies show correlation between the surrogate and clinical outcomes?
- Clinical Trial Evidence: Have other drugs shown that affecting the surrogate leads to clinical benefit?
- Consistency: Does the relationship hold across different patient populations and disease stages?
Confirmatory Trials: Verifying Clinical Benefit After Accelerated Approval
Accelerated approval is conditioned on the sponsor completing postmarketing confirmatory trials to verify and describe the clinical benefit. These trials are not optional - they are legally required conditions of approval.
Confirmatory Trial Requirements
| Requirement | Pre-FDORA (Before 2022) | Post-FDORA (2022 Onwards) |
|---|---|---|
| Trial Initiation | Required but timeline often flexible | Must be underway at time of approval |
| Completion Timeline | Negotiated with FDA | FDA sets specific deadlines |
| Progress Reports | Required annually | More frequent reporting required |
| Failure Consequences | Expedited withdrawal available | Streamlined withdrawal process |
| Extension Requests | Commonly granted | Greater scrutiny and justification required |
Types of Confirmatory Trials
Sponsors can fulfill confirmatory requirements through different approaches:
Traditional Clinical Endpoint Trial: A randomized controlled trial measuring clinical endpoints such as overall survival or symptom improvement.
Additional Surrogate Endpoint Data: In some cases, additional surrogate endpoint data may support conversion to traditional approval, particularly when combined with longer follow-up data.
Real-World Evidence: While still evolving, FDA has indicated openness to real-world evidence supporting clinical benefit in certain contexts.
Confirmatory Trial Design Considerations
When designing confirmatory trials for accelerated approval drugs, sponsors should consider:
- Control Arm: Typically requires an active control or placebo based on disease context
- Endpoints: Must include clinical endpoints that demonstrate direct patient benefit
- Population: Should include the full approved indication population
- Duration: Must be sufficient to observe clinical endpoints
- Statistical Power: Adequate to demonstrate statistically significant clinical benefit
“Strategic Insight: Many sponsors initiate confirmatory trials before accelerated approval, running them concurrently with pivotal surrogate endpoint trials. This approach can significantly reduce the overall time to traditional approval conversion.
Under FDORA, confirmatory trials must be "underway" at approval time. This doesn't necessarily mean enrollment is complete-it means the trial must be actively recruiting or enrolling patients. Build your timeline to have IRB approval and active site initiation before your target approval date. Delays in confirmatory trial activation after approval can trigger FDA enforcement action.
Accelerated Approval Drugs: Success Stories and Withdrawals
Understanding the track record of accelerated approval drugs provides important context for sponsors considering this pathway.
Accelerated Approval Success Metrics
| Metric | Value | Source |
|---|---|---|
| Total accelerated approvals (1992-2024) | 300+ | FDA |
| Oncology accelerated approvals | ~60% of total | FDA Oncology Center of Excellence |
| Conversion to traditional approval | ~60% | FDA analysis |
| Voluntary withdrawals | ~15% | FDA |
| FDA-initiated withdrawals | ~5% | FDA |
Notable Accelerated Approval Success Stories
Several accelerated approval drugs have demonstrated the pathway's value in getting important therapies to patients:
Imatinib (Gleevec): Received accelerated approval in 2001 for chronic myeloid leukemia based on cytogenetic response. Confirmatory trials demonstrated remarkable survival benefits, revolutionizing CML treatment.
Pembrolizumab (Keytruda): Initially received accelerated approval for melanoma in 2014. Has since gained multiple traditional approvals across numerous cancer types.
Venetoclax (Venclexta): Received accelerated approval in 2016 for chronic lymphocytic leukemia with 17p deletion based on overall response rate. Confirmatory trials validated clinical benefit, leading to expanded traditional approvals in combination regimens.
Accelerated Approval Withdrawals
Not all accelerated approval drugs successfully complete confirmatory trials. Understanding withdrawal patterns helps sponsors assess pathway risks:
Common Withdrawal Reasons:
- Confirmatory trial failed to demonstrate clinical benefit
- Confirmatory trial not completed in required timeframe
- Safety signals emerged in postmarketing surveillance
- Sponsor voluntarily withdrew based on commercial decisions
Notable Withdrawals:
- Several oncology drugs have been withdrawn after confirmatory trials failed to show overall survival benefit
- The accelerated approval pathway requires sponsors to accept that approval may be withdrawn if clinical benefit cannot be verified
FDA Accelerated Approval vs. Other Expedited Programs: Key Differences
FDA offers four expedited programs, and understanding how accelerated approval differs from the others helps sponsors select the right strategy.
Comparison of FDA Expedited Programs
| Feature | Accelerated Approval | Fast Track | Breakthrough Therapy | Priority Review |
|---|---|---|---|---|
| Type | Approval pathway | Designation | Designation | Review designation |
| Timing | At approval | During development | During development | At NDA/BLA submission |
| Key Benefit | Approval on surrogate endpoint | Rolling review, more FDA meetings | Intensive FDA guidance, rolling review | 6-month review vs. 10-month |
| Confirmatory Trials | Required postmarketing | Not required | Not required | Not required |
| Withdrawal Risk | Yes | No | No | No |
| Eligibility | Surrogate endpoint available | Serious condition, unmet need | Substantial improvement | Serious condition or significant advance |
How Expedited Programs Can Be Combined
Importantly, these programs are not mutually exclusive. A single drug can benefit from multiple expedited programs:
| Combination | Common Scenario |
|---|---|
| Fast Track + Accelerated Approval | Drug for serious condition with surrogate endpoint |
| Breakthrough Therapy + Accelerated Approval | Drug showing substantial improvement on surrogate endpoint |
| Accelerated Approval + Priority Review | Accelerated approval drugs typically receive priority review |
| Fast Track + Breakthrough Therapy + Accelerated Approval + Priority Review | Novel therapy for serious condition with strong preliminary data |
“Strategic Tip: Sponsors should evaluate eligibility for all expedited programs early in development. Combining programs maximizes FDA engagement and can significantly accelerate the development timeline.
Request breakthrough therapy designation even if pursuing accelerated approval. BTD provides rolling review, which allows you to submit complete data sections for CMC (Chemistry, Manufacturing, and Controls) and safety data before submitting efficacy data. This parallel review process can save 2-4 months compared to traditional sequential submission.
Choosing Between Accelerated Approval and Traditional Approval
The decision to pursue accelerated approval involves weighing benefits against risks:
Consider Accelerated Approval When:
- Treating a serious condition with clear unmet medical need
- A validated or reasonably likely surrogate endpoint exists
- Clinical endpoint trials would take significantly longer
- Patient population has limited treatment options
- Company can commit to rigorous postmarketing confirmatory trials
Consider Traditional Approval When:
- Clinical endpoint data can be obtained in reasonable timeframe
- Surrogate endpoint link to clinical benefit is uncertain
- Company cannot commit to postmarketing trial requirements
- Withdrawal risk is commercially unacceptable
- Payer coverage may be affected by accelerated approval status
FDORA Reforms: How the 2022 Law Changed Accelerated Approval
The Food and Drug Omnibus Reform Act (FDORA), enacted in December 2022, significantly strengthened FDA's accelerated approval program. These reforms address longstanding concerns about confirmatory trial completion.
Key FDORA Changes to Accelerated Approval
| Area | Pre-FDORA | Post-FDORA |
|---|---|---|
| Confirmatory Trial Timing | Could be initiated after approval | Must be underway at time of approval (with limited exceptions) |
| Timeline Enforcement | FDA had limited tools | FDA can set and enforce specific deadlines |
| Withdrawal Process | Required formal hearing | Streamlined expedited withdrawal procedures |
| Progress Reporting | Annual reports | More frequent reporting as specified by FDA |
| Failure Response | Lengthy withdrawal process | Faster action on failed confirmatory trials |
FDORA Pre-Approval Requirements
Under FDORA, sponsors must generally have confirmatory trials underway before accelerated approval is granted. This requirement ensures that verification of clinical benefit begins promptly.
Exceptions to Pre-Approval Trial Requirement:
- Ethical concerns with conducting trial before approval
- Insufficient disease incidence for pre-approval enrollment
- Other compelling reasons accepted by FDA
When an exception applies, sponsors must have a detailed confirmatory trial protocol in place at the time of approval.
FDORA Expedited Withdrawal Provisions
FDORA streamlined the withdrawal process for accelerated approval drugs that fail to verify clinical benefit:
Grounds for Expedited Withdrawal:
- Sponsor fails to conduct confirmatory trial with due diligence
- Confirmatory trial fails to verify clinical benefit
- Evidence demonstrates drug is not safe or effective
- Sponsor disseminates false or misleading promotional materials
Withdrawal Process:
- FDA provides sponsor notice of intent to withdraw
- Sponsor has 30 days to request informal hearing
- If hearing requested, FDA schedules within 60 days
- FDA issues final decision within 30 days of hearing
“Important Change: Under FDORA, the burden is now on the sponsor to demonstrate why accelerated approval should not be withdrawn, rather than FDA bearing the burden of proving withdrawal is warranted.
Impact of FDORA on Sponsor Strategy
FDORA reforms require sponsors to adapt their accelerated approval strategies:
Earlier Confirmatory Trial Planning: Sponsors must design and initiate confirmatory trials concurrent with pivotal surrogate endpoint trials.
More Conservative Timelines: With FDA setting enforceable deadlines, sponsors need realistic confirmatory trial completion estimates.
Enhanced Enrollment Strategies: Sponsors must demonstrate ability to complete enrollment in required timeframes.
Clearer Go/No-Go Decisions: The risk of expedited withdrawal makes confirmatory trial results more consequential.
Accelerated Approval Application Process: Step-by-Step Guide
Successfully navigating the accelerated approval pathway requires careful planning and execution at each stage.
Pre-Submission Phase
1. Assess Pathway Eligibility
- Confirm serious condition definition is met
- Document unmet medical need
- Identify appropriate surrogate endpoint
- Evaluate FDORA requirements for confirmatory trials
2. FDA Meeting Strategy
| Meeting Type | Timing | Key Objectives |
|---|---|---|
| Pre-IND | Before IND submission | Discuss pathway appropriateness, surrogate endpoint |
| End-of-Phase 2 | After Phase 2 data | Align on surrogate endpoint, confirmatory trial design |
| Type A (Pre-NDA/BLA) | 2-3 months before submission | Finalize submission content, PMR details |
3. Surrogate Endpoint Justification Package
- Scientific rationale for surrogate endpoint selection
- Literature supporting surrogate-clinical benefit relationship
- Epidemiological data if available
- Prior FDA precedent for surrogate endpoint use
Submission Phase
4. Accelerated Approval-Specific NDA/BLA Content
The application should include standard NDA/BLA components plus:
- Accelerated approval justification in Module 1
- Surrogate endpoint validation package
- Confirmatory trial protocol
- Proposed labeling with accelerated approval statement
- Postmarketing commitment timelines
5. Advisory Committee Considerations
FDA frequently convenes advisory committees for accelerated approval applications, particularly for:
- Novel surrogate endpoints
- Controversial benefit-risk profiles
- High-profile therapeutic areas
- First-in-class mechanisms
Post-Submission Phase
6. Review and Approval
Standard review timelines apply:
- Priority Review: 6 months
- Standard Review: 10 months
Most accelerated approval applications receive priority review.
7. Postmarketing Commitments
Upon approval, sponsors must:
- Execute confirmatory trial per agreed protocol
- Submit progress reports per FDA-specified schedule
- Report any emerging safety signals promptly
- Update labeling based on confirmatory trial results
Key Takeaways
Accelerated approval is an FDA regulatory pathway that allows drugs to be approved based on a surrogate endpoint reasonably likely to predict clinical benefit, rather than requiring direct evidence of clinical outcomes. This pathway is limited to drugs treating serious conditions with unmet medical needs and requires sponsors to complete postmarketing confirmatory trials to verify clinical benefit.
Key Takeaways
- Accelerated approval enables earlier patient access: This pathway allows approval based on surrogate endpoints for serious conditions with unmet medical needs, potentially saving years versus traditional approval.
- Surrogate endpoint selection is critical: The endpoint must be reasonably likely to predict clinical benefit, with biological plausibility and supporting evidence.
- Confirmatory trials are mandatory: Under FDORA, trials must typically be underway at approval and completed per FDA-specified timelines.
- Withdrawal risk is real: Approximately 20% of accelerated approvals have been withdrawn, either voluntarily or by FDA action.
- Strategic planning is essential: Successful accelerated approval requires early FDA engagement, concurrent confirmatory trial planning, and realistic timeline commitments.
- ---
Next Steps
The accelerated approval pathway offers a valuable route to market for therapies addressing serious conditions with unmet medical needs. However, success requires careful planning, strong surrogate endpoint justification, and commitment to rigorous confirmatory trials.
Organizations managing regulatory submissions benefit from automated validation tools that catch errors before gateway rejection. Assyro's AI-powered platform validates eCTD submissions against FDA, EMA, and Health Canada requirements, providing detailed error reports and remediation guidance before submission.
Sources
Sources
- FDA Expedited Programs for Serious Conditions - Guidance for Industry (2014)
- 21 CFR Part 314 Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses
- 21 CFR Part 601 Subpart E - Accelerated Approval of Biological Products
- Food and Drug Omnibus Reform Act of 2022 (FDORA)
- FDA CDER Accelerated Approval Program Statistics